Godavari Biorefineries Limited has made the audio recording of its first quarter FY27 (Q1FY27) earnings conference call available to investors and stakeholders. The recording, which captures the discussion on the company’s financial performance for the period ended June 30, 2026, was uploaded to the company’s official website on August 7, 2026. This move ensures transparency and allows those who could not attend the live dial-in session on August 7 to review management’s commentary on key operational metrics and strategic updates.

The disclosure was filed in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation letter, signed by Manoj Jain, Company Secretary & Compliance Officer, was submitted to both the National Stock Exchange of India Limited and BSE Limited. The filing confirms that the audio file is accessible via a direct link on the company’s corporate website, ensuring easy access for all market participants.

Earnings Call Overview

The earnings call took place on August 7, 2026, at 11:00 AM IST. Senior management members, including Samir Somaiya, Chairman & Managing Director, and Ashish Sinha, AGM, Investor Relations & Finance, addressed analysts and institutional investors. The session focused on reviewing the quarterly results and providing insights into the company’s future outlook.

Accessing the Recording

Investors can listen to the full audio recording through the link provided on Godavari Biorefineries’ official website. The file is hosted directly by the company to ensure data integrity and ease of access. For any technical issues or further inquiries regarding the investor relations process, stakeholders may contact Ashish Sinha at investorrelations@somaiya.com .

Compliance Details

The company reiterated that the conference call was conducted strictly for the purpose of discussing published information. No unpublished price-sensitive information was shared during the meeting. The compliance officer, Manoj Jain, confirmed the adherence to regulatory standards in the filing dated August 7, 2026. The complete schedule and related documents remain available on the company’s website for reference.

Godavari Biorefineries Ltd reported a net loss of ₹19.3 crore for the quarter ended June 30, 2026 (Q1 FY27), widening from a loss of ₹16.0 crore in the same period last year. The deterioration in profitability occurred despite a year-on-year increase in revenue from operations to ₹557.9 crore from ₹533.2 crore, highlighting significant margin pressure across key segments. Total income rose 4.9% to ₹559.9 crore, but this growth was insufficient to offset operational challenges and rising inventory costs.

The Board of Directors approved the unaudited financial results at its meeting held on August 05, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was submitted to the National Stock Exchange of India Limited and BSE Limited on August 06, 2026. Manoj Jain, Company Secretary & Compliance Officer, signed off on the disclosure.

Financial Performance

Revenue from operations for the quarter came in at ₹557.9 crore, compared to ₹533.2 crore in the prior year quarter. EBITDA contracted sharply to ₹2.6 crore from ₹6.5 crore in the same period last year, representing a decline of 60.5%. The EBITDA margin narrowed to 0.5% from 1.2% year-on-year. This represents a significant decline from the ₹92.1 crore EBITDA recorded in Q4 FY26. Gross profit decreased by 1.5% to ₹100.9 crore, with gross margin slipping to 18.0% from 19.2%. Finance costs declined to ₹13.9 crore from ₹15.3 crore, but this reduction was not enough to mitigate the operating loss.

Segment Dynamics

The bio-based chemicals segment emerged as a bright spot, delivering 53% EBITDA growth year-on-year. Its EBITDA margin expanded to 11.4% from 8.9% in Q1 FY26, reflecting benefits from debottlenecking initiatives completed in FY26 and a focus on higher-value specialty products. Samir Somaiya, Chairman & Managing Director, attributed this to robust revenue growth and healthy margin expansion within the division. Revenue from this segment grew 19.8% YoY to ₹168.7 crore.

Conversely, the ethanol segment's contribution to revenue mix shifted significantly. In Q1 FY27, ethanol accounted for 28% of revenue, down from 39% in Q1 FY26. Meanwhile, sugar and cogeneration saw its share rise to 40% from 33%. Bio-based chemicals maintained a steady 30% share, up slightly from 26%. The sugar and cogeneration segment reported an EBITDA loss of ₹14.6 crore, compared to a loss of ₹4.5 crore in Q1 FY26, driven by lower realizations despite improved sugar prices.

Operational Milestones

The company commissioned a 200 KLPD grain-based distillery at Sameerwadi during the quarter. This addition increases Godavari Biorefineries' total ethanol capacity to 800 KLPD, enhancing feedstock flexibility and operational resilience. Management stated this investment strengthens the ability to optimize operations across varying market conditions. The company is also exploring an additional 160 KLPD of fungible capacity to reach 360 KLPD within the existing limit to mitigate climate risks.

In R&D developments, the company secured an Indian patent for a cost-effective process to manufacture branched alcohols. Additionally, a Japanese patent was granted for a novel anti-cancer molecule. The company filed an application with the CDSCO for preliminary efficacy trials for its lead novel anti-cancer molecule MSP008-22 targeting Triple Negative Breast Cancer, with trials expected to commence in Q3 FY27, subject to regulatory approvals.

What the Numbers Show

The divergence between top-line growth and bottom-line performance is stark. While revenue grew year-on-year to ₹557.9 crore, EBITDA fell sharply to ₹2.6 crore from ₹6.5 crore, with the EBITDA margin compressing to 0.5% from 1.2%. This suggests that revenue growth was not accretive to operating margins, likely due to lower margins in the larger sugar and ethanol segments offsetting the high-margin performance of bio-based chemicals. The widening net loss indicates that fixed costs and finance charges remain significant burdens despite the reduction in interest expenses.